SeltaSquare

SeltaSquare (CEO Min-kyung Shin), an AI-driven pharmacovigilance (PV) and real-world data (RWD) company, announced on the 7th that it will participate as a Diamond Sponsor, the highest sponsorship tier, for the third consecutive year at the '2026 KoNECT International Conference (2026 KIC)', to be held at Lotte Hotel Seoul from October 13 to 15.

At this event, SeltaSquare will introduce 'AX PMS', a service that combines AI transformation (AX) and digital transformation (DX) for post-marketing surveillance (PMS). AX PMS systematically manages study operations as a whole and applies AI and digital technologies to document review and data verification, supporting expert review and decision-making at each stage. The company will also present its 'RWD Research' service, which supports drug safety assessment and evidence generation for regulatory and academic purposes.

At this year's conference in particular, SeltaSquare executives will speak at the Luncheon Session and the Pharmacovigilance Session, sharing their research and practical experience in RWD and pharmacovigilance.

Hye-jung Lee, Head of IE (Integrated Evidence) Strategy, will present on the 13th at the Luncheon Session under the title 'From RMP to Regulatory-Grade RWE'. In Korea, the re-examination system for new drugs was abolished in February 2025, and the post-marketing safety management framework was consolidated around the RMP. Lee will present an integrated evidence design centered on RWD and RWE, along with a full-lifecycle drug management strategy, tailored to this change.

Dong-wook Kim, Head of Data Center, will then speak on the 14th at the Pharmacovigilance Session on 'A Severity-Aware Framework for Pharmacovigilance Signal Detection'. He will explain a safety signal detection framework that takes the severity of adverse events into account, as well as analytical approaches that support experts' safety assessments.

SeltaSquare CEO Min-kyung Shin said, "Participating as a KIC Diamond Sponsor for three consecutive years is an opportunity to share with the industry the domain expertise SeltaSquare has built in pharmacovigilance and RWD, along with our AI technology." She added, "By improving PMS operational efficiency with AX and DX technologies and supporting RWD evidence generation suited to regulatory and academic purposes, we will help our clients respond to the changing regulatory environment with reliable evidence."

During the event, SeltaSquare will unveil key features of the 'AX PMS' service at its on-site booth, including integrated study management and document review support. The company also plans to offer expert consultations and on-site events for pharmaceutical and biotech professionals on streamlining PMS operational challenges and designing customized RWD studies.

The Original Article: [약업신문]셀타스퀘어, ‘KIC’ 3년 연속 다이아몬드 스폰서 참여…AI 기반 PMS 혁신·RWD 연구 전략 공개